Management of thrombosis in the antiphospholipid syndrome.
Optimal management of patients with the antiphospholipid syndrome (APS) remains a problem. There is now good evidence that those with thrombosis will be subject to recurrences and require long-term, possibly lifelong, oral anticoagulation. Steroids and immunosuppressive drugs aiming at a reduction of the antibody levels have not provided long-term benefit. Only prospective and controlled clinical trials can give a definitive answer to the optimal thrombotic prophylaxis in patients with the APS.
Khamashta
M A
MA
Lupus Research Unit, Rayne Institute, St Thomas' Hospital, London, UK.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000628:therapy*
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D007166:Immunosuppressive Agents